6 August 2025 – Biosceptre International Limited (“Biosceptre” or “the Company”) is pleased to announce an extension of the closing date for its ongoing placement of up to £10 million to existing shareholders who are eligible to participate under the laws and securities regulations of their respective jurisdictions.
The extension has been granted in response to strong shareholder engagement and to ensure that all eligible participants have adequate time to complete their applications. The Company remains focused on advancing its preclinical programs and preparations for clinical trials, supported by the continued commitment of its investor base.
To accommodate postal delays for shareholders who do not receive electronic communications and to mitigate the impact of the European summer holiday period, the closing date has been extended from 5:00pm GMT on 31 July 2025 to 5:00pm GMT on 8 September 2025.
Please note, this placement is not being offered to U.S. residents. Further, Biosceptre advises that this placement does not constitute an offer of securities in any jurisdiction in which such an offer would be unlawful or require registration.
Shareholders that are not residents of the US will receive updated communication with revised timelines and full participation details.
Biosceptre thanks its shareholders for their ongoing support and looks forward to continued progress in its mission to deliver innovative cancer therapies.
For further information, please contact:
Investor Relations
info@biosceptre.com